Pasi Janne
机构: Dana Farber Cancer Institute
每年引用次数
引用次数
引用: 134,728
H-指数: 163
I10-指数 : 547
出版物: 1,257
Are There Any Ethnic Differences in Molecular Predictors of Erlotinib Efficacy in Advanced Non-Small Cell Lung Cancer?
Myung-Ju Ahn , Byeong-Bae Park , Jin Seok Ahn , Sang We Kim
Clinical Cancer Research 14 ( 12) 3860 -3866
47
2008
Single-agent and combination therapeutic strategies to inhibit hepatocyte growth factor/MET signaling in cancer.
Luca Toschi , Pasi A. Jänne
Clinical Cancer Research 14 ( 19) 5941 -5946
105
2008
EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer
Jussi P. Koivunen , Craig Mermel , Kreshnik Zejnullahu , Carly Murphy
Clinical Cancer Research 14 ( 13) 4275 -4283
1,146
2008
Autocrine production of amphiregulin predicts sensitivity to both gefitinib and cetuximab in EGFR wild-type cancers.
Kimio Yonesaka , Kreshnik Zejnullahu , Neal Lindeman , Alison J. Homes
Clinical Cancer Research 14 ( 21) 6963 -6973
113
2008
Effects of Erlotinib in EGFR Mutated Non-Small Cell Lung Cancers with Resistance to Gefitinib
Daniel B. Costa , Kim-Son H. Nguyen , Byoung C. Cho , Lecia V. Sequist
Clinical Cancer Research 14 ( 21) 7060 -7067
136
2008
A Phase I Study with Neratinib (HKI-272), an Irreversible Pan ErbB Receptor Tyrosine Kinase Inhibitor, in Patients with Solid Tumors
Kwok-K. Wong , Paula M. Fracasso , Ronald M. Bukowski , Thomas J. Lynch
Clinical Cancer Research 15 ( 7) 2552 -2558
251
2009
Addition of S-1 to the Epidermal Growth Factor Receptor Inhibitor Gefitinib Overcomes Gefitinib Resistance in Non–small cell Lung Cancer Cell Lines with MET Amplification
Takafumi Okabe , Isamu Okamoto , Sayaka Tsukioka , Junji Uchida
Clinical Cancer Research 15 ( 3) 907 -913
45
2009
Multicenter, Randomized, Phase II Trial of CI-1033, an Irreversible Pan-ERBB Inhibitor, for Previously Treated Advanced Non-Small-Cell Lung Cancer
Pasi A. Jänne , Joachim von Pawel , Roger B. Cohen , Lucio Crino
Journal of Clinical Oncology 25 ( 25) 3936 -3944
101
2007
First-Line Gefitinib in Patients With Advanced Non–Small-Cell Lung Cancer Harboring SomaticEGFRMutations
Lecia V. Sequist , Renato G. Martins , David Spigel , Steven M. Grunberg
Journal of Clinical Oncology 26 ( 15) 2442 -2449
1,008
2008
Pemetrexed Plus Gemcitabine As First-Line Chemotherapy for Patients With Peritoneal Mesothelioma: Final Report of a Phase II Trial
George R. Simon , Claire F. Verschraegen , Pasi A. Jänne , Corey J. Langer
Journal of Clinical Oncology 26 ( 21) 3567 -3572
80
2008
Development of Small Molecules Targeting the Pseudokinase Her3
Sang Min Lim , Ting Xie , Kenneth D. Westover , Scott B. Ficarro
Bioorganic & Medicinal Chemistry Letters 25 ( 16) 3382 -3389
29
2015
Identification of oncogenic and drug-sensitizing mutations in the extracellular domain of FGFR2
Junko Tanizaki , Dalia Ercan , Marzia Capelletti , Michael Dodge
Cancer Research 75 ( 15) 3139 -3146
21
2015
Intratumoral Heterogeneity in EGFR-Mutant NSCLC Results in Divergent Resistance Mechanisms in Response to EGFR Tyrosine Kinase Inhibition.
Margaret Soucheray , Marzia Capelletti , Inés Pulido , Yanan Kuang
Cancer Research 75 ( 20) 4372 -4383
67
2015
Response Heterogeneity of EGFR and HER2 Exon 20 Insertions to Covalent EGFR and HER2 Inhibitors
Takayuki Kosaka , Junko Tanizaki , Raymond M. Paranal , Hideki Endoh
Cancer Research 77 ( 10) 2712 -2721
57
2017
CXCR7 reactivates ERK signaling to promote resistance to EGFR kinase inhibitors in NSCLC.
Jeffrey H. Becker , Yandi Gao , Margaret Soucheray , Ines Pulido
Cancer Research 79 ( 17) 4439 -4452
10
2019
Discovery of Inhibitors That Overcome the G1202R Anaplastic Lymphoma Kinase Resistance Mutation
John M. Hatcher , Magda Bahcall , Hwan Geun Choi , Yang Gao
Journal of Medicinal Chemistry 58 ( 23) 9296 -9308
27
2015
Chemically Induced Degradation of Anaplastic Lymphoma Kinase (ALK)
Chelsea E. Powell , Yang Gao , Li Tan , Katherine A. Donovan
Journal of Medicinal Chemistry 61 ( 9) 4249 -4255
131
2018
Activity of IPI-504, a Novel Heat-Shock Protein 90 Inhibitor, in Patients With Molecularly Defined Non–Small-Cell Lung Cancer
Lecia V. Sequist , Scott Gettinger , Neil N. Senzer , Renato G. Martins
Journal of Clinical Oncology 28 ( 33) 4953 -4960
294
2010
Treatment-Induced Tumor Dormancy through YAP-Mediated Transcriptional Reprogramming of the Apoptotic Pathway.
Kari J. Kurppa , Yao Liu , Ciric To , Tinghu Zhang
Cancer Cell 37 ( 1) 104 -122
214
2020
A Deregulated HOX Gene Axis Confers an Epigenetic Vulnerability in KRAS-Mutant Lung Cancers.
Stephanie L. Guerra , Ophélia Maertens , Ryan Kuzmickas , Thomas De Raedt
Cancer Cell 37 ( 5)
8
2020